Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 11Terminated 5Recruiting 5Active not recruiting 3Withdrawn 2Enrolling by invitation 1

Sponsor Class

INDUSTRY 2NIH 1NETWORK 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Paclitaxel 31Cyclophosphamide 30Cisplatin 29Bevacizumab 28Carboplatin 27Fluorouracil 24pembrolizumab 21Nivolumab 21Leucovorin 20Rituximab 19avelumab 18Gemcitabine 18Docetaxel 18Dexamethasone 18Capecitabine 17ALT-803 15130-nm albumin-bound paclitaxel 14Oxaliplatin 12Cetuximab 12fludarabine 11Ipilimumab 11venetoclax 10atezolizumab 10Radiosurgery 10Radiotherapy 9Pemetrexed 9Omacor 9Lenalidomide 9Bendamustine Hydrochloride 9yeast-CEA vaccine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × INDUSTRY × Observation × Clear all
NCT05292443 2024-02-23

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer

Geneplus-Beijing Co. Ltd.

Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT03770299 2022-03-24

CheckMate 9TN

Bristol-Myers Squibb

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡